$4.58B in CY2024 Part D spend218K claims · 84K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Risankizumab-Rzaa used for?
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriat....
Is there a generic for Risankizumab-Rzaa?
No. Risankizumab-Rzaa is brand-only with no generic equivalents currently in market.
How much does my plan pay for Risankizumab-Rzaa?
Across 329 Part D plans, Risankizumab-Rzaa averages $18476.52/unit (NADAC). Lowest available: $9679.49/unit. Highest in distribution: $22942.37/unit.
Is Risankizumab-Rzaa on the FDA shortage list?
No. Risankizumab-Rzaa is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.